Abstract
Background and Aims Obesity is closely associated with non-alcoholic fatty liver disease (NAFLD). We investigated expression of the CC-chemokine CCL25 in adipose tissue (AT) and its relation to hepatic inflammation.
Methods Primary human tissue was used for all experiments. CCL25 concentration in serum was measured with enzyme-linked immunosorbent assay (ELISA). Gene expression of CCL25 was measured with polymerase chain reaction. Protein expression was assessed with ELISA and immunohistochemistry. Leukocyte trafficking was investigated in a dynamic assay to model the hepatic sinusoid. Expression of CCR9 on liver-infiltrating leukocytes analysed with flow cytometry.
Results Circulating CCL25 was increased in obesity. Gene expression of CCL25 in AT was several-fold higher than in liver, although protein levels of CCL25 were comparable. Soluble CCL25 in flow media increased leukocyte trafficking across hepatic endothelium. Greater numbers of CCR9+ cells were seen in liver tissue from patients with NAFLD, where the greatest difference was in the number of CD14+CD16+ monocytes.
Conclusions CCL25 and its cognate receptor CCR9 mediate a novel pathway of inflammatory crosstalk between adipose and liver tissue in NAFLD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Young Investigators grant from the European Association for the Study of the Liver (EASL)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples of human liver tissue for isolation and culture of endothelial cells, gene expression analysis and immunohistochemistry were collected with the approval of Birmingham Research Ethics Committee (reference 06/Q2708/11). Plasma for measurement of CCL25 in human blood was obtained from the Human BioResource Centre (HBRC) at the University of Birmingham. The HBRC is licensed under the UK Human Tissue act (HTA) (licence 12358). It has research ethics committee (REC) approval to collect and distribute samples and data (North West REC, reference 15/NW/0079).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: RP: no conflicts of interest to declare
JD: no conflicts of interest to declare
CJW: no conflicts of interest to declare
DHA: no conflicts of interest to declare
JD: performed experiments, analysed data CJW: designed experiments, drafted manuscript
DHA: supervised experiment design, drafted manuscript All authors approved the final manuscript
Data Availability
Data are not publicly available but can sharing of anonymised experimental data can be discussed with the corresponding author